{"id":71489,"date":"2026-05-20T10:10:00","date_gmt":"2026-05-20T10:10:00","guid":{"rendered":"https:\/\/medsbase.com\/slu-pp-332\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"slu-pp-332","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/slu-pp-332\/","title":{"rendered":"SLU-PP-332 (Pan-ERR Agonista Mim\u00e9tico de Exerc\u00edcio)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 SLU-PP-332?<\/h3>\n<p style=\"margin: 0;\"><strong>SLU-PP-332<\/strong> (CAS 303760-60-3, MF C<sub>18<\/sub>H<sub>14<\/sub>N<sub>2<\/sub>O<sub>2<\/sub>, MW 290,3 g\/mol) \u00e9 uma pequena mol\u00e9cula sint\u00e9tica <strong>pan-agonista dos receptores relacionados ao estrog\u00eanio<\/strong> (ERR\u03b1 \/ ERR\u03b2 \/ ERR\u03b3) developed in the Burris clinical at Saint Louis University. ERRs are orphan nuclear-receptor transcription factors that drive mitochondrial biogenesis, fatty-acid oxidation, oxidative-fibre development, and the muscle-adaptation programme normally engaged by exercise \u2014 making SLU-PP-332 a leading <strong>\u201cmim\u00e9tico de exerc\u00edcio\u201d<\/strong> tool. Published in Billon et al. (2023, <em>ACS Chemical Biology<\/em>) \u2014 dose \u00fanica aguda induz uma assinatura gen\u00e9tica de resposta ao exerc\u00edcio aer\u00f3bico no m\u00fasculo esquel\u00e9tico; dosagem cr\u00f4nica aumenta a propor\u00e7\u00e3o de fibras oxidativas Tipo IIa e melhora a capacidade de resist\u00eancia em camundongos. <em>Pequena mol\u00e9cula \u2014 n\u00e3o um pept\u00eddeo.<\/em> Note: some supplier batches are labelled SLU-PP-322 \/ SLU-PP-332 interchangeably \u2014 both refer to the same Burris-lab ERR pan-agonist; consult COA for batch-specific identification. For clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic small-molecule pan-agonist of estrogen-related receptors (ERR\u03b1 \/ ERR\u03b2 \/ ERR\u03b3); orphan nuclear-receptor agonist; exercise-mimetic tool; <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">SLU-PP-332 (sin\u00f4nimos: SLU-PP-322 em alguns lotes de fornecedores; agonista pan-ERR; Composto 332 do laborat\u00f3rio Burris)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">303760-60-3 (can\u00f4nico, conforme MedKoo \/ MedChemExpress \/ literatura cient\u00edfica)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>18<\/sub>H<sub>14<\/sub>N<sub>2<\/sub>O<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">290,32 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agonista pan de <strong>ERR\u03b1, ERR\u03b2, ERR\u03b3<\/strong> receptores nucleares com seletividade ~4 vezes maior para ERR\u03b1 em rela\u00e7\u00e3o a ERR\u03b3. EC<sub>50<\/sub> ERR\u03b1 ~98 nM (Billon et al. 2023). A ativa\u00e7\u00e3o do receptor ERR impulsiona a transcri\u00e7\u00e3o de genes alvo de PGC-1\u03b1 \u2014 biog\u00eanese mitocondrial (TFAM, NRF1, NRF2), \u03b2-oxida\u00e7\u00e3o de \u00e1cidos graxos (CPT1B, MCAD, LCAD), subunidades do complexo de fosforila\u00e7\u00e3o oxidativa e cadeias pesadas de miosina do tipo fibras oxidativas. O efeito l\u00edquido imita o programa transcricional de adapta\u00e7\u00e3o ao exerc\u00edcio.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (composto sint\u00e9tico de pequena mol\u00e9cula \u2014 n\u00e3o \u00e9 um pept\u00eddeo)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">DMSO \u226550 mg\/mL; solubilidade aquosa moderada (sub-mg\/mL). Para trabalho in vitro, prepare estoques de DMSO e dilua em meio de cultura imediatamente antes do uso. Para trabalho in vivo, as formula\u00e7\u00f5es geralmente usam sistemas de co-solventes como DMSO\/PEG\/solu\u00e7\u00e3o salina ou similares.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C a curto prazo, \u221220 \u00b0C a longo prazo (\u226536 meses). DMSO reconstitu\u00eddo: \u221220 \u00b0C, uso \u00fanico ap\u00f3s descongelamento. Proteger da luz. Evitar ciclos repetidos de congelamento-descongelamento.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Pan-Agonismo ERR Impulsiona a Transcri\u00e7\u00e3o de Adapta\u00e7\u00e3o ao Exerc\u00edcio<\/h2>\n<p>SLU-PP-332 \u00e9 o agonista pan-ERR sint\u00e9tico de pequena mol\u00e9cula mais citado na literatura publicada. ERRs (receptores relacionados ao estrog\u00eanio \u03b1, \u03b2, \u03b3) s\u00e3o receptores nucleares \u00f3rf\u00e3os que compartilham o dom\u00ednio de liga\u00e7\u00e3o ao DNA dos receptores de estrog\u00eanio, mas n\u00e3o se ligam ao estrog\u00eanio \u2014 s\u00e3o constitutivamente ativos na aus\u00eancia de qualquer ligante end\u00f3geno natural e, em vez disso, s\u00e3o regulados pela liga\u00e7\u00e3o de coativadores (principalmente PGC-1\u03b1). ERRs s\u00e3o os principais impulsionadores transcricionais de:<\/p>\n<ul>\n<li><strong>Biog\u00eanese mitocondrial<\/strong> \u2014 controle transcricional direto de TFAM, NRF1, NRF2 e dezenas de genes de importa\u00e7\u00e3o de prote\u00ednas mitocondriais<\/li>\n<li><strong>\u03b2-oxida\u00e7\u00e3o de \u00e1cidos graxos<\/strong> \u2014 indu\u00e7\u00e3o de CPT1B (carnitina palmitoiltransferase 1B), MCAD, LCAD e outras enzimas de \u03b2-oxida\u00e7\u00e3o<\/li>\n<li><strong>Fosforila\u00e7\u00e3o oxidativa<\/strong> \u2014 transcri\u00e7\u00e3o de subunidades de complexos ETC codificadas nuclearmente<\/li>\n<li><strong>Desenvolvimento de fibras oxidativas<\/strong> \u2014 Indu\u00e7\u00e3o da cadeia pesada de miosina tipo IIa (oxidative fast-twitch); convers\u00e3o de fibras glicol\u00edticas tipo IIb para fibras oxidativas tipo IIa<\/li>\n<li><strong>Adapta\u00e7\u00e3o no manejo da glicose<\/strong> \u2014 melhora da sensibilidade \u00e0 insulina no m\u00fasculo esquel\u00e9tico em modelos de camundongos DIO<\/li>\n<\/ul>\n<p>Este \u00e9 o mesmo programa transcricional ativado pela adapta\u00e7\u00e3o ao exerc\u00edcio mediada pelo PGC-1\u03b1 \u2014 tornando o agonismo pan-ERR uma via farmacol\u00f3gica direta para o fen\u00f3tipo de adapta\u00e7\u00e3o ao exerc\u00edcio. O estudo de Billon et al. (2023) <em>ACS Chemical Biology<\/em> demonstrou que uma dose \u00fanica aguda de SLU-PP-332 produz uma assinatura de express\u00e3o g\u00eanica no m\u00fasculo esquel\u00e9tico de camundongos que se sobrep\u00f5e substancialmente com a assinatura produzida por uma sess\u00e3o de corrida volunt\u00e1ria em roda \u2014 e a dosagem cr\u00f4nica (50 mg\/kg\/d IP por 4 semanas) aumenta a propor\u00e7\u00e3o de fibras tipo IIa e a resist\u00eancia em esteira em camundongos. Trabalhos subsequentes (Billon et al. 2024, al\u00edvio da s\u00edndrome metab\u00f3lica) demonstraram efeitos de melhora metab\u00f3lica em camundongos DIO, incluindo melhora na toler\u00e2ncia \u00e0 glicose e redu\u00e7\u00e3o da esteatose hep\u00e1tica. <\/p>\n<h2>Published Evidence<\/h2>\n<ul>\n<li><strong>Farmacologia do receptor pan-ERR<\/strong> \u2014 agonista pan-ERR de pequena mol\u00e9cula de refer\u00eancia can\u00f4nica<\/li>\n<li><strong>Exercise-mimetic transcriptional studies<\/strong> \u2014 publicado como o principal composto \u201cexerc\u00edcio em uma p\u00edlula\u201d ao lado de <a href=\"https:\/\/medsbase.com\/pt-br\/aicar-acadesine\/\">AICAR<\/a>; mecanicamente distinto (direto via ERR vs mim\u00e9tico de AMP via AMPK)<\/li>\n<li><strong>Mitochondrial biogenesis studies<\/strong> \u2014 ativador transcricional direto do eixo TFAM\/NRF1\/NRF2<\/li>\n<li><strong>Skeletal-muscle adaptation studies<\/strong> \u2014 indu\u00e7\u00e3o de fibras oxidativas tipo IIa, fen\u00f3tipo de desempenho de resist\u00eancia<\/li>\n<li><strong>Metabolic-syndrome studies<\/strong> \u2014 modelos de camundongos DIO, esteatose hep\u00e1tica, sensibilidade \u00e0 insulina<\/li>\n<li><strong>Farmacologia da via PGC-1\u03b1<\/strong> \u2014 ativa a cascata transcricional dirigida pela PGC-1\u03b1 a jusante<\/li>\n<\/ul>\n<p>Para um contexto mais amplo, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/aicar-acadesine\/\">AICAR<\/a> (mim\u00e9tico do exerc\u00edcio mediado pela AMPK can\u00f4nica \u2014 mecanismo diferente), <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> (lipolytic-only fat-loss peptide), <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo derivado mitocondrial), <a href=\"https:\/\/medsbase.com\/pt-br\/5-amino-1mq\/\">5-Amino-1MQ<\/a> (inibidor de NNMT do eixo NAD), <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD\u207a<\/a> (coenzima de transporte de el\u00e9trons). <\/p>\n<h2>Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong> \u2014 studies standard; supports DIO mouse cohorts at 50 mg\/kg\/d \u00d74\u20138 wk and in-vitro pharmacology at nM-\u00b5M concentrations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Como Comparar \u2014 SLU-PP-332 vs AICAR<\/h2>\n<p>SLU-PP-332 e <a href=\"https:\/\/medsbase.com\/pt-br\/aicar-acadesine\/\">AICAR<\/a> are the two most-cited &#8220;exercise mimetic&#8221; compounds in this catalogue, but they engage the exercise-adaptation programme through mechanistically distinct upstream routes. SLU-PP-332 directly activates the ERR family (the downstream transcription factor for the mitochondrial-biogenesis programme). AICAR activates AMPK (the upstream energy-sensor kinase that, among many other effects, drives PGC-1\u03b1 expression and PGC-1\u03b1-ERR co-activation). The two compounds therefore converge on the same downstream gene-expression signature but engage it from different points of the regulatory cascade. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px;\">SLU-PP-332<\/th>\n<th style=\"padding: 10px;\">AICAR<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>MW<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">290,32 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">258,23 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonista direto do receptor nuclear ERR\u03b1\/\u03b2\/\u03b3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ativador de AMPK (via ZMP intracelular)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Ponto de interven\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fator de transcri\u00e7\u00e3o downstream<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Quinase sensor de energia upstream<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Foco mais estudado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indu\u00e7\u00e3o de fibras oxidativas tipo IIa, fen\u00f3tipo de resist\u00eancia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sensibilidade \u00e0 insulina, gliconeog\u00eanese hep\u00e1tica, farmacologia mais ampla da AMPK<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50 mg\/kg\/dia IP (rato, protocolo Billon)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mg\/kg\/dia IP (rato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Atualmente sem nome<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos (S4.5)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p>Frascos liofilizados: armazenar a 2\u20138 \u00b0C a curto prazo, \u221220 \u00b0C a longo prazo. Reconstituir em DMSO em estoque de trabalho \u226510 mg\/mL (a solubilidade em \u00e1gua \u00e9 limitada; DMSO \u00e9 o solvente preferido). Para trabalho in vivo, formular com co-solventes (DMSO\/PEG-400\/salina ou similar) logo antes da administra\u00e7\u00e3o. Armazenar estoques de DMSO a \u221220 \u00b0C, uso \u00fanico ap\u00f3s descongelamento. Proteger da luz. Evitar ciclos repetidos de congelamento-descongelamento. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O \u201cSLU-PP-322\u201d \u00e9 o mesmo que SLU-PP-332?<\/h3>\n<p>Alguns lotes de fornecedores usam \u201cSLU-PP-322\u201d e \u201cSLU-PP-332\u201d de forma intercambi\u00e1vel para o mesmo agonista pan-ERR do laborat\u00f3rio Burris. A designa\u00e7\u00e3o cient\u00edfica can\u00f4nica \u00e9 SLU-PP-332 (Billon et al. 2023, ACS Chemical Biology), com CAS 303760-60-3. Consulte o COA do lote para identifica\u00e7\u00e3o definitiva. <\/p>\n<h3>Quais faixas de dose publicadas foram utilizadas?<\/h3>\n<p>Protocolos in-vivo em camundongos usam 50 mg\/kg\/dia IP por 4\u20138 semanas (protocolo can\u00f4nico de Billon et al.). A farmacologia in-vitro de miotubos e c\u00e9lulas musculares prim\u00e1rias usa de 100 nM a 10 \u00b5M em meio de crescimento. EC<sub>50<\/sub> no ERR\u03b1 \u00e9 ~98 nM. <\/p>\n<h3>Como o SLU-PP-332 difere de outros mim\u00e9ticos de exerc\u00edcio?<\/h3>\n<p>O SLU-PP-332 ativa diretamente os ERRs \u2014 os fatores de transcri\u00e7\u00e3o downstream. O AICAR ativa a AMPK (quinase upstream). Os agonistas de PPAR\u03b4 da d\u00e9cada de 2010 (GW501516) ativam um programa transcricional diferente, mas parcialmente sobreposto. Mecanismo diferente, sa\u00edda parcialmente sobreposta. <\/p>\n<h3>O SLU-PP-332 est\u00e1 na Lista de Proibidos da WADA?<\/h3>\n<p>Not currently under its specific name, but the broader S4 class (Hormone and Metabolic Modulators) includes exercise-mimetic compounds. The compound&#8217;s regulatory status may evolve as more data accumulates. Users in human-subject contexts should consult the current WADA list. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Exercise-Mimetic \/ Metabolic Compounds<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/aicar-acadesine\/\"><strong>AICAR<\/strong><\/a> \u2014 Mim\u00e9tico de exerc\u00edcio can\u00f4nico mediado por AMPK \u2014 mecanismo complementar<\/li>\n<li><a href=\"\/pt-br\/aod-9604\/\"><strong>AOD-9604<\/strong><\/a> \u2014 Fragmento C-terminal do hGH apenas lipol\u00edtico<\/li>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Pept\u00eddeo metab\u00f3lico derivado mitocondrial ativador de AMPK<\/li>\n<li><a href=\"\/pt-br\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 Inibidor de NNMT \u2014 poupador de precursor do eixo NAD<\/li>\n<li><a href=\"\/pt-br\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 Suplementa\u00e7\u00e3o direta do pool de dinucleot\u00eddeos<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Pequena mol\u00e9cula sint\u00e9tica pan-agonista dos receptores nucleares ERR\u03b1\/\u03b2\/\u03b3<br \/>\n\u2705 Ativador transcricional direto da biog\u00eanese mitocondrial + indu\u00e7\u00e3o de fibras oxidativas<br \/>\n\u2705 Leading exercise-mimetic compound (Billon et al. 2023, ACS Chem Biol)<br \/>\n\u2705 EC\u2085\u2080 ERR\u03b1 ~98 nM; ~4 vezes mais seletivo para ERR\u03b1 em rela\u00e7\u00e3o ao ERR\u03b3<br \/>\n\u2705 Alguns fornecedores rotulam como SLU-PP-322; nome can\u00f4nico SLU-PP-332; CAS 303760-60-3, MW 290.32<\/p>\n<p><strong>SLU-PP-332<\/strong> contains synthetic pan-ERR small-molecule compound. Not a peptide.<\/p>","protected":false},"featured_media":71525,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6536,6489,6535,6534,6482,6533,6532],"class_list":["post-71489","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-burris-lab-compound","product_tag-exercise-mimetic","product_tag-mitochondrial-biogenesis","product_tag-pan-err-agonist","product_tag-research-compound","product_tag-slu-pp-322","product_tag-slu-pp-332","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71489"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71525"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71489"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71489"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71489"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}